Pricing in the Market for Anticancer Drugs
In 2011, Bristol-Myers Squibb set the price of its newly approved melanoma drug ipilimumab— brand name Yervoy—at $120,000 for a course of therapy. The drug was associated with an incremental increase in life expectancy of four months. Drugs like ipilimumab have fueled the perception that the launch...
Main Authors: | Howard, David H., Bach, Peter B., Berndt, Ernst R., Conti, Rena M. |
---|---|
Other Authors: | Sloan School of Management |
Format: | Article |
Language: | en_US |
Published: |
American Economic Association
2015
|
Online Access: | http://hdl.handle.net/1721.1/96183 https://orcid.org/0000-0002-6388-0768 |
Similar Items
-
The generic drug user fee amendments: an economic perspective
by: Conti, Rena M, et al.
Published: (2019) -
International Reference Pricing in the Context of U.S. Drug Policy
by: Frank, Richard, et al.
Published: (2022) -
Regulating Drug Prices while Increasing Innovation
by: Conti, Rena M, et al.
Published: (2022) -
Price indexes for clinical trial research: a feasibility study
by: Berndt, Ernst R, et al.
Published: (2019) -
Energy price changes and the induced revaluation of durable capital in U.S. manufacturing during the OPEC decade
by: Berndt, Ernst R., et al.
Published: (2011)